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ABSTRACT: Phospholipase A2, group XVI (PLA2G16) is a thiol hydrolase from the HRASLS family that regulates lipolysis in
adipose tissue and has been identiﬁed as a host factor enabling the cellular entry of picornaviruses. Chemical tools are essential
to visualize and control PLA2G16 activity, but they have not been reported to date. Here, we show that MB064, which is a
ﬂuorescent lipase probe, also labels recombinant and endogenously expressed PLA2G16. Competitive activity-based protein
proﬁling (ABPP) using MB064 enabled the discovery of α-ketoamides as the ﬁrst selective PLA2G16 inhibitors. LEI110 was
identiﬁed as a potent PLA2G16 inhibitor (Ki = 20 nM) that reduces cellular arachidonic acid levels and oleic acid-induced
lipolysis in human HepG2 cells. Gel-based ABPP and chemical proteomics showed that LEI110 is a selective pan-inhibitor of
the HRASLS family of thiol hydrolases (i.e., PLA2G16, HRASLS2, RARRES3 and iNAT). Molecular dynamic simulations of
LEI110 in the reported crystal structure of PLA2G16 provided insight in the potential ligand−protein interactions to explain its
binding mode. In conclusion, we have developed the ﬁrst selective inhibitor that can be used to study the cellular role of
PLA2G16.
Phospholipase A2, group XVI (PLA2G16), was ﬁrstisolated in murine ﬁbroblasts as a product of the
HRASLS gene family, which also includes the phospholipase/
acyltransferases, namely, phospholipid metabolizing enzyme
A-C1 (A-C1), HRAS-like suppressor 2 (HRASLS2), Retinoid
acid receptor responder protein 3 (RARRES3), and Ca2+-
independent N-acyltransferase (iNAT).1−3 PLA2G16 is an
intercellular, single-pass transmembrane thiol hydrolase with a
molecular weight of 18 kDa that predominantly hydrolyzes
the sn-2 fatty acyl chain of phosphatidylcholine.4,5 PLA2G16
has a papain-fold motive consisting of three α-helices and ﬁve
antiparallel β-sheets organized in a circular permutation and a
conserved catalytic triad consisting of Cys113, His23, and
His35, as determined by X-ray crystallography (PDB code:
4DOT) and site-directed mutagenesis studies.6−9
PLA2G16 is found in various cell lines (e.g., HepG2)10,11
and adipose tissue.12,13 Its expression is induced during
adipocyte diﬀerentation.14,15 PLA2G16 regulates lipolysis, and
its genetic ablation prevented obesity in mice induced by a
high fat diet or leptin deﬁciency.16 Recently, PLA2G16 was
identiﬁed as a host factor for picornaviruses, which cause the
common cold, by facilitating viral genome translocation and
preventing clearance of the virus in host cells.17,18 Taken
together, these genetic studies highlight the therapeutic
potential of PLA2G16. However, to date, there are no
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PLA2G16 inhibitors reported that can be used as
pharmacological tools to validate PLA2G16 as a therapeutic
target.
Activity-based protein proﬁling (ABPP) is a powerful
chemical biological technique that allows eﬃcient lead
discovery studies by assessing inhibitor activity and selectivity
in complex, native proteomes.19,20 ABPP makes use of
chemical probes that covalently react with the catalytic amino
acid in an activity-dependent manner. The activity-based
probe (ABP) contains a warhead linked to a ﬂuorophore or
biotin reporter tag for ﬂuorescent- or mass-spectrometry-
based detection, respectively. Currently, no ABPs have been
reported for PLA2G16 that could enable inhibitor discovery.
Previously, we have developed and applied the β-lactone-
based probe (MB064) as a broad-spectrum probe for the
identiﬁcation of highly potent and selective diacylglycerol
lipase inhibitors.21,22 In addition, MB064 was instrumental in
the discovery of the oﬀ-target proﬁle of the fatty acid amide
hydrolase inhibitor BIA 10−2474 that caused the death of a
volunteer in a clinical phase 1 study.23 The β-lactone is a
warhead that covalently reacts with the catalytic serine in
many serine hydrolases, forming an acyl-enzyme intermediate.
Interestingly, MB064 has also been reported to form thioester
bonds with the catalytic cysteine of various enzymes.24 Here,
we report that MB064 labels PLA2G16 in an activity-
dependent manner and is able to visualize endogenous
PLA2G16 in adipose tissue. Screening of a focused lipase
inhibitor library using ABPP and subsequent hit optimization
resulted in the identiﬁcation of α-ketoamide LEI110 as a
selective PLA2G16 inhibitor that reduces cellular arachidonic
acid levels and oleic acid-induced lipolysis in human HepG2
cells.
Previously, we have developed MB064 as an ABP for
diacylglycerol lipase-α/β (structure shown in Figure 1A).21
MB064 could cross-react with many enzymes that employed
a serine or cysteine as a nucleophile,22 thereby making it an
excellent chemical tool to proﬁle inhibitor activity and
selectivity on endogenously expressed enzymes in various
biological samples. To test whether MB064 could also label
PLA2G16, we incubated MB064 with proteomes of
transiently overexpressed human PLA2G16-FLAG in human
embryonic kidney 293 T (HEK293T) cells, followed by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and ﬂuorescent scanning. A ﬂuorescent band
was observed at the expected MW, which overlapped with a
band visualized by the FLAG-tag antibody and was absent in
mock-transfected cells (Figure 1B). The labeling was probe-
and protein-concentration-dependent (Figure 1C) and was
optimal at pH 8, which is consistent with previously reported
pH dependency of PLA2G16.14,25 Site-directed mutagenesis
of the catalytic Cys113 into alanine or serine abolished or
signiﬁcantly reduced labeling, respectively, whereas its
expression was not substantially altered as witnessed by
FLAG-tag antibodies (Figure 1D). Of note, MB064 was also
able to cross-react with HRASLS2, RARRES3, and iNAT
(Figure S2 in the Supporting Information (SI)). Finally, we
tested whether MB064 could also label endogenously
expressed PLA2G16. To this end, we incubated MB064
with freshly isolated mouse white adipose tissue (WAT) and
brown adipose tissue (BAT) proteomes. A ﬂuorescent band
was visualized at the expected MW, which also overlapped
with a band observed by PLA2G16 antibodies (Figure 1E).
Taken together, these results demonstrate that MB064 can
eﬃciently label active human PLA2G16 via a covalent bond
with Cys113 and visualizes native mouse PLA2G16 in brown
and white adipose tissue.
Having identiﬁed MB064 as a suitable chemical probe
targeting PLA2G16, we set out to screen a small focused
library of 50 lipase inhibitors at 10 μM in a competitive
ABPP format. This led to discovery of 4-(4-chlorophenyl)-2-
oxo-N-phenethylbutan-amide, an α-ketoamide (compound 1)
as a hit that almost completely abolished PLA2G16 labeling
at 10 μM (Figure 2A).
Figure 1. Characterization of MB064 as an ABP for PLA2G16. (A) Chemical structure of probe MB064. (B) ABPP using MB064 with
PLA2G16 membrane (mem) or cytosol (cyt) proteome (1 mg mL−1) transiently expressed in HEK293T cells and Western blot of the ABPP
gel using an anti-FLAG antibody. (C) ABPP condition optimization for human PLA2G16 cytosol proteome using MB064. For the probe
concentration test, 0.5 mg mL−1 protein lysate was used. For the protein concentration test, probe of 500 nM was used. (D) ABPP using
MB064 with diﬀerent hPLA2G16 constructs, and Western blot of the ABPP gel using an anti-FLAG antibody. (E) Labeling of endogenous
PLA2G16 in WAT and BAT cytosol proteome by MB064, and Western blot of the ABPP gel using an anti-PLA2G16 antibody (full gels are
given in the SI).
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Compound 1 was resynthesized using previously reported
procedures (see the Materials and Methods section) and
tested in a concentration−response ABPP assay. Compound
1 displayed a half-maximum inhibitory concentration (pIC50
± SEM) of 6.0 ± 0.1 (n = 3) (Figure 2B). Furthermore, it
demonstrated similar activity on the other proteins of the
HRASLS-gene family (HRASLS2, RARRES3, and iNAT)
with a pIC50 in the range of 6.0−6.2 (Figure 3B, Table 1).
Next, we conﬁrmed the inhibitory activity of compound 1 in
a previously reported orthogonal biochemical ﬂuorescence
assay that uses the Green/Red Bodipy PC-A2 as a surrogate
substrate (with a KM of 7.8 ± 2.2 μM) and cytosol PLA2G16
fraction of HEK293T cells overexpressing human PLA2G16.8
Compound 1 displayed a Ki value of 84 nM (95% conﬁdence
interval CI: 72−96 nM) (Figure 2C). α-Ketoamides have
previously been reported to inhibit serine hydrolases
expressed in the brain.26−29 To determine the selectivity of
compound 1 on endogenously expressed serine hydrolases,
we performed a competitive ABPP experiment in mouse
brain proteomes using the broad-spectrum serine hydrolase
ABPs, ﬂuorophosphonate (FP)-TAMRA, and MB064. Com-
pound 1 (10 μM) did not reduce the labeling of any proteins
in mouse brain targeted by FP-TAMRA or MB064 (Figure
2D). Taken together, these results indicate that α-ketoamide
1 is a selective inhibitor of PLA2G16 and its family members.
To improve the inhibitory activity of 1, a hit optimization
program was initiated in which 64 analogues were
synthesized (data not shown). This resulted in the discovery
of 2-oxo-5-phenyl-N-(4-((5-(triﬂuoromethyl)pyridin-2-yl)-
oxy)-phenethyl)pentanamide (LEI110) as a PLA2G16
inhibitor with a 10-fold increased potency (pIC50 = 7.0 ±
0.1), compared to compound 1 in the ABPP-assay (Figures
3A and 3B). LEI110 was also active on HRASLS2,
RARRES3, and iNAT (Figure 3B, Table 1). LEI110
demonstrated a Ki value of 20 nM (95% CI: 17−24 nM)
in the biochemical PLA2G16 assay (Figure 3C) and was
selective over brain serine hydrolases as determined with a
gel-based ABPP assay (Figure S7 in the SI). PLA2G16 is
endogenously expressed in brown and white adipose tissue,
and its activity could be visualized by MB064 (Figure 3D);
therefore, we tested whether compound 1 and LEI110 were
able to block PLA2G16 activity in adipose tissue. Indeed,
both compounds completely abolished labeling of native
PLA2G16 by MB064, whereas the labeling of other proteins
in brown and white adipose tissue was not aﬀected (Figure
3D). The selectivity of LEI110 in adipose tissue was
conﬁrmed in a chemical proteomics assay using MB108
(THL-biotin) and FP-biotin, respectively (Figures 3E and 3F,
respectively; see structures in Figure S1 in the Supporting
Information).30 Based on its activity and selectivity proﬁle, we
decided to test LEI110 in a cellular assay. To this end, we
transfected human PLA2G16 in U2OS cells and incubated
them with vehicle (DMSO) or LEI110 (10 μM) under
serum-free conditions. This led to a time-dependent increase
in arachidonic acid, a product of PLA2G16, as determined by
targeted lipidomics, which could be almost completely
abolished by LEI110 (Figure 3G). Taken together, these
results indicate that LEI110 is a potent, selective, and cell-
permeable PLA2G16 inhibitor.
Genetic studies have previously demonstrated that
PLA2G16 regulates lipolysis;16,31 therefore, we tested whether
LEI110 modulates lipolysis in human hepatocytes. Stimula-
tion of HepG2 cells with oleic acid induces steatosis that
eventually results in lipid droplet formation, as visualized by
Adipored, and is a widely used in vitro model to study fatty
liver diseases.32,33 Since PLA2G16 activity could not be
observed in HepG2 cells using our ABPP method, probably
due to its low abundance, we conﬁrmed PLA2G16 mRNA
expression in HepG2 cells via qPCR (Table S2 in the SI). Of
Figure 2. Discovery and biochemical characterization of compound 1. (A) Chemical structure of 1. (B) Dose−response curves for 1 on
PLA2G16 (left) and other HRASLS members, HRASLS2, RARRES3, and iNAT (right) measured by competitive ABPP using cytosol proteome
prepared from transfected HEK293T cells with probe MB064. Under the curves are the corresponding ABPP gels: concentration-dependent
inhibition of 1 against diﬀerent proteins (n = 3). (C) Dose−response curve of 1 for PLA2G16 (cytosol proteome prepared from PLA2G16
overexpressing HEK293T cells) with the PC-A2 ﬂuorescent substrate assay (n = 3). (D) Selectivity of 1 against MB064 and FP-TAMRA in
mouse brain membrane (mem) and cytosol (cyt) proteome. Coomassie was used as a protein loading control. Minus sign (−) indicates control
(with DMSO), plus sign (+) indicates with 1 at 10 μM.
Table 1. pIC50 ± SEM (n = 3) of Compound 1 and
LEI110 against HRASLS Protein Family Members from
the ABPP Assay
pIC50 ± SEM
compound PLA2G16 HRASLS2 RARRES3 iNAT
1 6.0 ± 0.1 6.2 ± 0.1 6.2 ± 0.1 6.4 ± 0.1
LEI110 7.0 ± 0.1 6.8 ± 0.1 6.8 ± 0.1 7.6 ± 0.1
ACS Chemical Biology Letters
DOI: 10.1021/acschembio.8b00969
ACS Chem. Biol. 2019, 14, 164−169
166
note, very low mRNA levels for the other HRASLS-gene
family members were found. In addition, the selectivity of
LEI110 in HepG2 cells was conﬁrmed in a chemical
proteomics assay with MB108 and FP-biotin (Figure S8 in
the SI). Next, we incubated HepG2 cells with LEI110 (10
μM) before oleic acid treatment and observed a reduction in
lipid droplet formation, which indicates that LEI110
modulates lipolysis (Figure 3H). This is consistent with
previous reports showing that PLA2G16 modulates lipid
metabolism in HepG2 cells or adipocytes.16,31
Finally, to gain insight in the molecular interactions of α-
ketoamides with PLA2G16, LEI110 and 1 were docked in a
PLA2G16 crystal structure (PDB: 4DOT).6 We envisioned
that the electrophilic ketone of LEI110 and 1 could act
through a reversible covalent mechanism with the active site
Cys113 forming a hemithioacetal adduct, similar to other
reported α-ketoamide inhibitors.34 LEI110 and 1 were thus
covalently attached to Cys113 in the enzyme and a molecular
dynamics simulation was performed (Figure 3I). Hydrogen
bonding of the oxyanion with His23 was observed in both
cases, as well as π−π stacking with Tyr21. The extension of
the ketone alkyl chain by one methylene allows for a more
optimal π-cation interaction with Arg18 for LEI110,
compared to 1. Furthermore, the introduction of the pyridyl
moiety in LEI110 enables an additional hydrogen bond with
the Tyr21-OH. These docking results provide a potential
explanation for the 10-fold increase in activity seen for
LEI110.
In conclusion, we have applied competitive ABPP using
MB064 to discover α-ketoamides as the ﬁrst selective
PLA2G16 inhibitors. LEI110 was identiﬁed as a potent
PLA2G16 inhibitor (Ki = 20 nM) that reduces cellular
arachidonic acid levels in PLA2G16-overexpressing U2OS
cells and oleic acid-induced steatosis in human HepG2 cells.
Gel-based ABPP and chemical proteomics showed that
LEI110 is a selective pan-inhibitor of the HRASLS-family
of thiol hydrolases (i.e., HRASLS2, RARRES3, and iNAT).
Molecular dynamic simulations of LEI110 in the reported
crystal structure of PLA2G16 provided insight in the
potential ligand−protein interactions to explain its binding
mode. α-Ketoamides have previously been employed as
warheads for the inhibition of hydrolases35−37 and are
incorporated in marketed drugs for the treatment of the
viral infection with hepatitis C (e.g., boceprevir);38,39
therefore, it is anticipated that LEI110 constitutes an
excellent starting point for the structure-based drug develop-
ment of novel molecular therapies for obesity and/or the
common cold.
Figure 3. Biochemical characterization of LEI110. (A) Chemical structure of LEI110. (B) Dose−response curves of LEI110 against PLA2G16
and other HRASLS family members with probe MB064. (C) Dose−response curve of LEI110 for PLA2G16 with the PC-A2 ﬂuorescent
substrate assay. (D) Competitive ABPP of compound 1 and LEI110 against endogenous PLA2G16, using MB064 in the cytosol proteome of
mouse WAT and BAT and Western blot of the ABPP gel using an anti-PLA2G16 antibody. Both inhibitors could compete the activity of
PLA2G16 at 10 μM. (E) MB108 and FP-biotin based chemoproteomic analysis of serine hydrolase activities in the mouse WAT cytosol
proteome treated with LEI110 (10 μM). (F) MB108 and FP-biotin based chemoproteomic analysis of serine hydrolase activities in the mouse
BAT cytosol proteome treated with LEI110 (10 μM). (G) In situ treatment of U2OS cells overexpressing PLA2G16 with LEI110 (10 μM, 4 or
8 h) reduced arachidonic acid (AA) levels that were induced by PLA2G16. (H) In situ treatment of HepG2 cells with LEI110 (10 μM, 24 h)
reversed the lipid accumulation in the cells induced by oleic acid (OA, 100 μM, 24 h). (I) Structure-guided modeling of 1 and LEI110.
Compounds 1 (blue) and LEI110 (orange) in complex with PLA2G16, covalently bound to Cys113. Green dotted lines represent a hydrogen
bond, pink and purple represent π-interactions. Data represent mean values ± SEM for at least three replicates. [Legend: *, p < 0.05; **, p <
0.01; ***, p < 0.001 using the Student’s t-test.]
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■ METHODS
All methods are described in the Supporting Information.
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